Adam B. Weiner, Urologist at Cedars Sinai Medical Center, shared a post on X:
“STAMPEDE: AI biomarker may help select who needs abi intensification in VHR localized prostate cancer
Just out in Annals of Oncology.
- >1k pts w/ non-metastatic very high-risk PCa from 2 randomized STAMPEDE phase 3 abi trials.
- Multimodal AI using routine H&E + PSA/stage/age
- MMAI very high-risk: abi + LT-ADT markedly improved MFS: HR 0.47. 5-yr MFS 81% vs 62%.
- MMAI standard high-risk: benefit was limited: HR 0.83. 5-yr MFS 84% vs 82%. Interaction P=0.02.
- Signal in both node-negative and node-positive pts
- Implication: intensify where benefit is increased, spare overtreatment/toxicity where benefit is reduced.”
Title: Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer
Authors: C. Parker, H-C. Huang, E. Grist, L. Mendes, R. Yamashita, D. Croucher, A. Sachdeva, L. Murphy, V. Liu, S. Santos Vidal, T. Todorovic, S. Lall, M. Goncalves, S. Thakali, A. Wingate, L. Zakka, D. Wetterskog, K. Nowakowska, C. Amos, D. Berney, P. Tran, D. Spratt, M. Sydes, L. Brown, S. Zhao, P. Nguyen, N. Clarke, C. Sweeney, E. Stewart, M. Parmar, A. Esteva, N. James, G. Attard
Read the Full Article.
Other articles featuring Adam Weiner on OncoDaily.
